A multi-centre, comparative, double blind, randomised cross-over trial investigating single dose pharmacokinetics and safety of turoctocog alfa pegol from the pivotal process and turoctocog alfa pegol from the commercial process in patients with severe haemophilia A.
Phase of Trial: Phase I
Latest Information Update: 18 Dec 2017
At a glance
- Drugs Turoctocog alfa pegol (Primary)
- Indications Haemophilia A
- Focus Pharmacokinetics
- Acronyms pathfinder™7
- Sponsors Novo Nordisk
- 26 Apr 2017 Status changed from active, no longer recruiting to completed.
- 28 Mar 2017 Status changed from recruiting to active, no longer recruiting.
- 14 Mar 2017 This trial was completed in Spain, according to eudra record.